{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:50:45Z","timestamp":1793922645645,"version":"4.8.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.ymgme.2018.11.008","type":"journal-article","created":{"date-parts":[[2018,11,17]],"date-time":"2018-11-17T11:45:45Z","timestamp":1542455145000},"page":"162-168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Antibodies against recombinant alpha-galactosidase A in Fabry disease: Subclass analysis and impact on response to treatment"],"prefix":"10.1016","volume":"126","author":[{"given":"S.J.","family":"van der Veen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.B.P.","family":"van Kuilenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.E.M.","family":"Hollak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.H.P.","family":"Kaijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Voorberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Langeveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2018.11.008_bb0005","series-title":"The Online Metabolic and Molecular Bases of Inherited Disease","article-title":"\u03b1-Galactosidase A Deficiency: Fabry Disease","author":"Desnick","year":"2014"},{"issue":"5","key":"10.1016\/j.ymgme.2018.11.008_bb0010","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2016090964","article-title":"Characterization of classical and nonclassical fabry disease: a multicenter study","volume":"28","author":"Arends","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.ymgme.2018.11.008_bb0015","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ymgme.2017.05.001","article-title":"Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease","volume":"121","author":"Arends","year":"2017","journal-title":"Mol Genet Metab"},{"issue":"10","key":"10.1016\/j.ymgme.2018.11.008_bb0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047805","article-title":"Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome","volume":"7","author":"Rombach","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ymgme.2018.11.008_bb0025","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2012030316","article-title":"Agalsidase benefits renal histology in young patients with Fabry disease","volume":"24","author":"Tondel","year":"2013","journal-title":"J Am Soc Nephrol"},{"issue":"19","key":"10.1016\/j.ymgme.2018.11.008_bb0030","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1161\/CIRCULATIONAHA.108.841494","article-title":"Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy","volume":"119","author":"Thurberg","year":"2009","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ymgme.2018.11.008_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173358","article-title":"Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies","volume":"12","author":"El Dib","year":"2017","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.ymgme.2018.11.008_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182379","article-title":"Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors","volume":"12","author":"Arends","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ymgme.2018.11.008_bb0045","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1681\/ASN.2014121226","article-title":"Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease","volume":"27","author":"Lenders","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.ymgme.2018.11.008_bb0050","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ymgme.2011.12.006","article-title":"Anti-alpha-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry","volume":"105","author":"Wilcox","year":"2012","journal-title":"Mol Genet Metab"},{"issue":"5","key":"10.1016\/j.ymgme.2018.11.008_bb0055","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/jmedgenet-2017-104863","article-title":"Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study","volume":"55","author":"Arends","year":"2018","journal-title":"J Med Genet"},{"issue":"1","key":"10.1016\/j.ymgme.2018.11.008_bb0060","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13023-018-0877-4","article-title":"Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY","volume":"13","author":"Mauhin","year":"2018","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"10.1016\/j.ymgme.2018.11.008_bb0065","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.ymgme.2018.11.008_bb0070","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2008.10.004","article-title":"A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease","volume":"96","author":"Benichou","year":"2009","journal-title":"Mol Genet Metab"},{"issue":"3","key":"10.1016\/j.ymgme.2018.11.008_bb0075","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1373\/clinchem.2012.192138","article-title":"Quantification of globotriaosylsphingosine in plasma and urine of fabry patients by stable isotope ultraperformance liquid chromatography-tandem mass spectrometry","volume":"59","author":"Gold","year":"2013","journal-title":"Clin Chem"},{"key":"10.1016\/j.ymgme.2018.11.008_bb0080","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jchromb.2011.11.020","article-title":"Quantification of the Fabry marker lysoGb3 in human plasma by tandem mass spectrometry","volume":"883\u2013884","author":"Kruger","year":"2012","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"2013","key":"10.1016\/j.ymgme.2018.11.008_bb0085","first-page":"1","article-title":"Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO","year":"2012","journal-title":"Kidney International Supplements"},{"issue":"8","key":"10.1016\/j.ymgme.2018.11.008_bb0090","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1093\/ndt\/gfu320","article-title":"Analysis of risk factors associated with renal function trajectory over time: a comparison of different statistical approaches","volume":"30","author":"Leffondre","year":"2015","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.ymgme.2018.11.008_bb0095","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1093\/ndt\/gfq306","article-title":"Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy","volume":"26","author":"Sanchez-Nino","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"10.1016\/j.ymgme.2018.11.008_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136442","article-title":"Epithelial-Mesenchymal Transition in Kidney Tubular Epithelial Cells Induced by Globotriaosylsphingosine and Globotriaosylceramide","volume":"10","author":"Jeon","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2018.11.008_bb0105","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.neulet.2015.01.084","article-title":"The Fabry disease-associated lipid Lyso-Gb3 enhances voltage-gated calcium currents in sensory neurons and causes pain","volume":"594","author":"Choi","year":"2015","journal-title":"Neurosci Lett"},{"issue":"10","key":"10.1016\/j.ymgme.2018.11.008_bb0110","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1182\/blood-2016-06-720086","article-title":"Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A","volume":"129","author":"Cannavo","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ymgme.2018.11.008_bb0115","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2012-07-444877","article-title":"Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients","volume":"121","author":"Whelan","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ymgme.2018.11.008_bb0120","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.clinthera.2016.11.017","article-title":"Long-term immunogenicity of elosulfase alfa in the treatment of morquio a syndrome: results from MOR-005, a phase III extension study","volume":"39","author":"Long","year":"2017","journal-title":"Clin Ther"},{"issue":"2","key":"10.1016\/j.ymgme.2018.11.008_bb0125","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1208\/s12248-016-9878-1","article-title":"Pre-existing antibody: biotherapeutic modality-based review","volume":"18","author":"Gorovits","year":"2016","journal-title":"AAPS J"},{"issue":"6","key":"10.1016\/j.ymgme.2018.11.008_bb0130","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.jaci.2017.12.1001","article-title":"Characterization of drug-neutralizing antibodies in patients with Fabry disease during infusion","volume":"141","author":"Lenders","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.ymgme.2018.11.008_bb0135","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1365-2141.2008.07232.x","article-title":"IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A","volume":"142","author":"van Helden","year":"2008","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.ymgme.2018.11.008_bb0140","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/hae.12646","article-title":"A longitudinal evaluation of anti-FVIII antibodies demonstrated IgG4 subclass is mainly correlated with high-titer inhibitor in hemophilia A patients","volume":"21","author":"Montalvao","year":"2015","journal-title":"Hemophilia"},{"key":"10.1016\/j.ymgme.2018.11.008_bb0145","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.ymgme.2018.11.008_bb0150","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3389\/fimmu.2018.00097","article-title":"A New Classification System for IgG4 Autoantibodies","volume":"9","author":"Koneczny","year":"2018","journal-title":"Front Immunol"},{"issue":"51","key":"10.1016\/j.ymgme.2018.11.008_bb0155","doi-asserted-by":"crossref","first-page":"20783","DOI":"10.1073\/pnas.1313944110","article-title":"MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4","volume":"110","author":"Huijbers","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.ymgme.2018.11.008_bb0160","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1208\/s12248-012-9340-y","article-title":"Immunogenicity to therapeutic proteins: impact on PK\/PD and efficacy","volume":"14","author":"Chirmule","year":"2012","journal-title":"AAPS J"},{"issue":"4","key":"10.1016\/j.ymgme.2018.11.008_bb0165","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s40268-017-0211-y","article-title":"Pharmacokinetic Effects of Antidrug Antibodies Occurring in Healthy Subjects After a Single Dose of Intravenous Infliximab","volume":"17","author":"Ehrenpreis","year":"2017","journal-title":"Drugs R D"},{"issue":"8","key":"10.1016\/j.ymgme.2018.11.008_bb0170","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.ymgme.2018.11.008_bb0175","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/joim.12647","article-title":"Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease","volume":"282","author":"Lenders","year":"2017","journal-title":"J Intern Med"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719218305092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719218305092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,2]],"date-time":"2019-02-02T07:17:04Z","timestamp":1549091824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719218305092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S1096719218305092"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2018.11.008","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibodies against recombinant alpha-galactosidase A in Fabry disease: Subclass analysis and impact on response to treatment","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2018.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}